Sun releases what it says are promising interim data from a Phase II study on Ilumya, its flagship first novel biologic, in the additional indication of psoriatic arthritis, where the antibody met the primary endpoint in its first trial in this setting.
Last year, generics-focused Sun Pharmaceutical Industries Ltd. launched its first novel biologic, Ilumya (tildrakizumab), in the US and Europe for moderate to severe plaque psoriasis.
Now the Indian firm, which is pivoting its portfolio to higher-margin specialty drugs from cheaper generics, is looking to expand Ilumya’s use to treat psoriatic arthritis, where it has just reported “promising” results from an
Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’
Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.
Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.
